Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-15025 Alone and With Tislelizumab in Advanced Solid Tumors
NCT04649385Phase 1Completed
- Sponsor
- BeiGene
- Start
- Mar 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of BGB-15025 in solid tumor (2 arms), sponsored by BeiGene. Primary endpoints: Dose Limiting Toxicities up to 1 year, Adverse Events up to 3 years and 4 more. Started Mar 2021; status: completed.
02
Drugs
BGB-15025
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04649385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04649385.